B

Bergenbio ASA
OSE:BGBIO

Watchlist Manager
Bergenbio ASA
OSE:BGBIO
Watchlist
Price: 8.767 NOK -5.16%
Market Cap: 342.7m NOK
Have any thoughts about
Bergenbio ASA?
Write Note

EV/OCF
Enterprise Value to OCF

-1.2
Current
-166.6
Median
6.1
Industry
Higher than median
Lower than industry value

Enterprise Value to Operating Cash Flow (EV/OCF) ratio is a valuation multiple that measures the value of a company, debt included, to the operating cash flow it generates.

EV/OCF
-1.2
=
Enterprise Value
167.8m NOK
/
Operating Cash Flow
-139m NOK
All Countries
Close
Market Cap EV/OCF
NO
Bergenbio ASA
OSE:BGBIO
342.7m NOK -1.2
FR
Pharnext SCA
OTC:PNEXF
6T USD -241 761.3
US
Abbvie Inc
NYSE:ABBV
315.4B USD 22.2
US
Amgen Inc
NASDAQ:AMGN
142B USD 26.2
US
Gilead Sciences Inc
NASDAQ:GILD
111.1B USD 10.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
106.2B USD -116.9
US
Epizyme Inc
F:EPE
94.1B EUR -465.7
AU
CSL Ltd
ASX:CSL
139B AUD 34.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.8B USD 17.3
US
Seagen Inc
F:SGT
39.3B EUR -72.8
NL
argenx SE
XBRU:ARGX
38.2B EUR -139.9
 
NO
B
Bergenbio ASA
OSE:BGBIO
Average EV/OCF: 22.2
Negative Multiple: -1.2
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -241 761.3
US
Abbvie Inc
NYSE:ABBV
22.2
US
Amgen Inc
NASDAQ:AMGN
26.2
US
Gilead Sciences Inc
NASDAQ:GILD
10.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -116.9
US
E
Epizyme Inc
F:EPE
Negative Multiple: -465.7
AU
CSL Ltd
ASX:CSL
34.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -72.8
NL
argenx SE
XBRU:ARGX
Negative Multiple: -139.9

EV/OCF Forward Multiples

Forward EV/OCF multiple is a version of the EV/OCF ratio that uses forecasted operating cash flow for the EV/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/OCF
N/A
2-Years Forward
EV/OCF
N/A
3-Years Forward
EV/OCF
N/A